5-methyl-3-(phenylamino)-2-(4-(pyridin-2-yl)benzyl)-7-((tetrahydrofuran-2-yl)methyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione | 960064-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methyl-3-(phenylamino)-2-(4-(pyridin-2-yl)benzyl)-7-((tetrahydrofuran-2-yl)methyl)-2H-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione
• 英文别名: 3-Anilino-5-methyl-7-(oxolan-2-ylmethyl)-2-[(4-pyridin-2-ylphenyl)methyl]pyrazolo[3,4-d]pyrimidine-4,6-dione
• CAS: 960064-83-9
• 化学式: C₂₉H₂₈N₆O₃
• 分子量: 508.58
• InChiKey: BHSMCJPUJATFHJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  92.6
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• ORGANIC COMPOUNDS
  申请人：Li Peng

  公开号：US20100173878A1

  公开（公告）日：2010-07-08

  2-benzyl-3-(optionally hetero)arylamino-[2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-diones, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors.

  2-苄基-3-(可选杂环)芳基氨基-[2H]-吡唑并[3,4-d]嘧啶-4,6(5H,7H)-二酮，以自由、盐或前药形式，可用作药物，特别是作为磷酸二酯酶1抑制剂。
• PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS
  申请人：Intra-Cellular Therapies, Inc.

  公开号：EP2400970A1

  公开（公告）日：2012-01-04
• US9255099B2
  申请人：——

  公开号：US9255099B2

  公开（公告）日：2016-02-09
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2007143705A2

  公开（公告）日：2007-12-13

  [EN] 2-(optionally hetero)arylmethyl-3 -(optionally hetero)arylamino- [2H] -pyrazolo [3,4-d] pyrimidine-4,6(5H, 7H)-diones, in free, salt or prodrug form are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors.
  [FR] La présente invention concerne des 2-(facultativement hétéro)arylméthyl-3-(facultativement hétéro)arylamino-[2H]-pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-diones, sous forme libre, de sel ou de promédicament utiles en tant que substances pharmaceutiques, en particulier en tant qu'inhibiteurs de phosphodiestérase 1.
• [EN] PDE 1 INHIBITORS FOR OPHTHALMIC DISORDERS<br/>[FR] INHIBITEUR DE PDE 1 POUR TROUBLES OPHTALMIQUES
  申请人：INTRA CELLULAR THERAPIES INC

  公开号：WO2010098839A1

  公开（公告）日：2010-09-02

  Compounds that inhibit phosphodiesterase 1 (PDE1) are useful to treat glaucoma or elevated intraocular pressure. The PDE1 inhibitors may be administered as monotherapy or in combination with additional intraocular-pressure lowering agents. In addition, the invention provides ophthalmic compositions comprising PDE 1 inhibitors and optionally one or more additional intraocular pressure- lowering agents. Topical and systemic therapy may be used.